메뉴 건너뛰기




Volumn 113, Issue 3, 2012, Pages 725-734

Immunotherapy for metastatic melanoma

Author keywords

Antibodies; Cancer; Ctla 4; Dendritic Cells; Immunotherapy; Melanoma; T Cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; DACARBAZINE; DENDRITIC CELL VACCINE; EMD 273063; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; IPILIMUMAB; MDX 1106; MONOCLONAL ANTIBODY; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 2; SIPULEUCEL T; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; URELUMAB;

EID: 84857615145     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23402     Document Type: Article
Times cited : (19)

References (79)
  • 4
    • 80051706186 scopus 로고    scopus 로고
    • TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity
    • Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N. 2011. TLR4 engagement during TLR3-induced pro-inflammatory signaling in dendritic cells promotes IL-10-mediated suppression of anti-tumor immunity. Cancer Res. 71:5467-5476.
    • (2011) Cancer Res , vol.71 , pp. 5467-5476
    • Bogunovic, D.1    Manches, O.2    Godefroy, E.3    Yewdall, A.4    Gallois, A.5    Salazar, A.M.6    Marie, I.7    Levy, D.E.8    Bhardwaj, N.9
  • 6
    • 85044869427 scopus 로고    scopus 로고
    • Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells
    • abstr 2534
    • Brentjens RJ, Riviere I, Park J, Davilla M, Wang X, Yeh R, Lamanna N, Frattini MG, Sadelain M. 2011. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. J Clin Oncol 29:18s (abstr 2534).
    • (2011) J Clin Oncol 29
    • Brentjens, R.J.1    Riviere, I.2    Park, J.3    Davilla, M.4    Wang, X.5    Yeh, R.6    Lamanna, N.7    Frattini, M.G.8    Sadelain, M.9
  • 7
    • 34748815649 scopus 로고    scopus 로고
    • GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
    • DOI 10.1016/j.vaccine.2007.06.038, PII S0264410X07007049
    • Brichard VG, Lejeune D. 2007. GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61-B71. (Pubitemid 47488551)
    • (2007) Vaccine , vol.25 , Issue.SUPPL. 2
    • Brichard, V.G.1    Lejeune, D.2
  • 9
    • 75149127319 scopus 로고    scopus 로고
    • IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells
    • Caserta S, Alessi P, Basso V, Mondino A. 2010. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells. Eur J Immunol 40(2):470-479.
    • (2010) Eur J Immunol , vol.40 , Issue.2 , pp. 470-479
    • Caserta, S.1    Alessi, P.2    Basso, V.3    Mondino, A.4
  • 12
    • 63149163677 scopus 로고    scopus 로고
    • The role of TNF superfamily members in T-cell function and diseases
    • Croft M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9(4):271-285.
    • (2009) Nat Rev Immunol , vol.9 , Issue.4 , pp. 271-285
    • Croft, M.1
  • 13
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • Curran MA, Montalvo W, Yagita H, Allison JP. 2010a. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275-4280.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.9 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 18
    • 54849437711 scopus 로고    scopus 로고
    • Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters
    • Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. 2009. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58(1):1-14.
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.1 , pp. 1-14
    • Engell-Noerregaard, L.1    Hansen, T.H.2    Andersen, M.H.3    Thor Straten, P.4    Svane, I.M.5
  • 21
    • 0022478367 scopus 로고
    • Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
    • Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ. 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232(4749): 506-508. (Pubitemid 16052365)
    • (1986) Science , vol.232 , Issue.4749 , pp. 506-508
    • Grabstein, K.H.1    Urdal, D.L.2    Tushinski, R.J.3
  • 23
    • 77951134921 scopus 로고    scopus 로고
    • Interleukin-21: Updated review of Phase i and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
    • Hashmi MH, Van Veldhuizen PJ. 2010. Interleukin-21: Updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 10(5):807-817.
    • (2010) Expert Opin Biol Ther , vol.10 , Issue.5 , pp. 807-817
    • Hashmi, M.H.1    Van Veldhuizen, P.J.2
  • 28
    • 56349142086 scopus 로고    scopus 로고
    • Immune modulation by melanoma-derived factors
    • Ilkovitch D, Lopez DM. 2008. Immune modulation by melanoma-derived factors. Exp Dermatol 17(12):977-985.
    • (2008) Exp Dermatol , vol.17 , Issue.12 , pp. 977-985
    • Ilkovitch, D.1    Lopez, D.M.2
  • 30
    • 0037126021 scopus 로고    scopus 로고
    • Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.
    • (2002) Proc Natl Acad Sci USA , vol.99 , Issue.19 , pp. 12293-12297
    • Iwai, Y.1    Ishida, M.2    Tanaka, Y.3    Okazaki, T.4    Honjo, T.5    Minato, N.6
  • 31
    • 70350359819 scopus 로고    scopus 로고
    • Chemotherapy and biologic therapies for melanoma: Do they work?
    • Jilaveanu LB, Aziz SA, Kluger HM. 2009. Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol 27(6):614-625.
    • (2009) Clin Dermatol , vol.27 , Issue.6 , pp. 614-625
    • Jilaveanu, L.B.1    Aziz, S.A.2    Kluger, H.M.3
  • 32
    • 33750324618 scopus 로고    scopus 로고
    • Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
    • Johnson LA, Heemskerk B, Powell DJ, Jr., Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177(9):6548-6559. (Pubitemid 44628874)
    • (2006) Journal of Immunology , vol.177 , Issue.9 , pp. 6548-6559
    • Johnson, L.A.1    Heemskerk, B.2    Powell Jr., D.J.3    Cohen, C.J.4    Morgan, R.A.5    Dudley, M.E.6    Robbins, P.F.7    Rosenberg, S.A.8
  • 37
    • 33646794392 scopus 로고    scopus 로고
    • Checkpoint blockade in cancer immunotherapy
    • DOI 10.1016/S0065-2776(06)90008-X, PII S006527760690008X
    • Korman AJ, Peggs KS, Allison JP. 2006. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339. (Pubitemid 43765802)
    • (2006) Advances in Immunology , vol.90 , pp. 297-339
    • Korman, A.J.1    Peggs, K.S.2    Allison, J.P.3
  • 40
    • 78449242173 scopus 로고    scopus 로고
    • E4697 Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma
    • (abstr 8504)
    • Lawson DH, Lee SJ, Tarhini AA, Margolin KA, Ernstoff MS, Kirkwood JM. 2010. E4697 Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 28:15s (abstr 8504).
    • (2010) J Clin Oncol , vol.28
    • Lawson, D.H.1    Lee, S.J.2    Tarhini, A.A.3    Margolin, K.A.4    Ernstoff, M.S.5    Kirkwood, J.M.6
  • 41
    • 33646440024 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
    • Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 24(13):e20-e22.
    • (2006) J Clin Oncol , vol.24 , Issue.13
    • Lamers, C.H.1    Sleijfer, S.2    Vulto, A.G.3    Kruit, W.H.4    Kliffen, M.5    Debets, R.6    Gratama, J.W.7    Stoter, G.8    Oosterwijk, E.9
  • 42
    • 68549106145 scopus 로고    scopus 로고
    • Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2
    • Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD. 2009. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother 58(10):1565-1576.
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.10 , pp. 1565-1576
    • Le Graham, H.K.L.1    Miller, C.H.2    Kmieciak, M.3    Manjili, M.H.4    Bear, H.D.5
  • 44
    • 79251496050 scopus 로고    scopus 로고
    • Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma
    • (abstr 8560)
    • Lutzky J, Lawson DH, Enriquez-Nunez Y, Gabrilovich D. 2010. Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma. J Clin Oncol 28:15s (abstr 8560).
    • (2010) J Clin Oncol , vol.28
    • Lutzky, J.1    Lawson, D.H.2    Enriquez-Nunez, Y.3    Gabrilovich, D.4
  • 45
    • 77950576363 scopus 로고    scopus 로고
    • Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis
    • Mocellin S, Pasquali S, Rossi CR, Nitti D. 2010. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 102(7):493-501.
    • (2010) J Natl Cancer Inst , vol.102 , Issue.7 , pp. 493-501
    • Mocellin, S.1    Pasquali, S.2    Rossi, C.R.3    Nitti, D.4
  • 47
    • 80054680991 scopus 로고    scopus 로고
    • Treating cancer with genetically engineered T cells
    • [Epub ahead of print]
    • Park TS, Rosenberg SA, Morgan RA. 2011. Treating cancer with genetically engineered T cells. Trends Biotechnol [Epub ahead of print].
    • (2011) Trends Biotechnol
    • Park, T.S.1    Rosenberg, S.A.2    Morgan, R.A.3
  • 50
    • 77949407794 scopus 로고    scopus 로고
    • Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma
    • Rasmussen MA, Colding-Jorgensen M, Hansen LT, Bro R. 2010. Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol 69(4):379-390.
    • (2010) Br J Clin Pharmacol , vol.69 , Issue.4 , pp. 379-390
    • Rasmussen, M.A.1    Colding-Jorgensen, M.2    Hansen, L.T.3    Bro, R.4
  • 51
    • 55949137090 scopus 로고    scopus 로고
    • Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
    • (abstr. LBA9011)
    • Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M. 2008. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:15s (abstr. LBA9011).
    • (2008) J Clin Oncol , vol.26
    • Ribas, A.1    Hauschild, A.2    Kefford, R.3    Punt, C.J.4    Haanen, J.B.5    Marmol, M.6    Garbe, C.7    Gomez-Navarro, J.8    Pavlov, D.9    Marshall, M.10
  • 52
    • 68949208645 scopus 로고    scopus 로고
    • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    • Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. 2009. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med 7:68.
    • (2009) J Transl Med , vol.7 , pp. 68
    • Ribas, A.1    Kirkwood, J.M.2    Atkins, M.B.3    Whiteside, T.L.4    Gooding, W.5    Kovar, A.6    Gillies, S.D.7    Kashala, O.8    Morse, M.A.9
  • 57
    • 65249173447 scopus 로고    scopus 로고
    • Adoptive cell therapy for the treatment of patients with metastatic melanoma
    • Rosenberg SA, Dudley ME. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21(2):233-240.
    • (2009) Curr Opin Immunol , vol.21 , Issue.2 , pp. 233-240
    • Rosenberg, S.A.1    Dudley, M.E.2
  • 60
    • 77957744369 scopus 로고    scopus 로고
    • Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
    • Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207(10):2187-2194.
    • (2010) J Exp Med , vol.207 , Issue.10 , pp. 2187-2194
    • Sakuishi, K.1    Apetoh, L.2    Sullivan, J.M.3    Blazar, B.R.4    Kuchroo, V.K.5    Anderson, A.C.6
  • 62
    • 80051580618 scopus 로고    scopus 로고
    • Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
    • Siegel R, Ward E, Brawley O, Jemal A. 2011. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236.
    • (2011) CA Cancer J Clin , vol.61 , Issue.4 , pp. 212-236
    • Siegel, R.1    Ward, E.2    Brawley, O.3    Jemal, A.4
  • 67
    • 0029037061 scopus 로고
    • Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colonystimulating factor, and TNF-alpha
    • Szabolcs P, Moore MA, Young JW. 1995. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colonystimulating factor, and TNF-alpha. J Immunol 154(11):5851-5861.
    • (1995) J Immunol , vol.154 , Issue.11 , pp. 5851-5861
    • Szabolcs, P.1    Moore, M.A.2    Young, J.W.3
  • 70
    • 79952269861 scopus 로고    scopus 로고
    • Ipilimumab: A promising immunotherapy for melanoma
    • Thumar JR, Kluger HM. 2010. Ipilimumab: A promising immunotherapy for melanoma. Oncology (Williston Park) 24(14):1280-1288.
    • (2010) Oncology (Williston Park) , vol.24 , Issue.14 , pp. 1280-1288
    • Thumar, J.R.1    Kluger, H.M.2
  • 72
    • 0033517152 scopus 로고    scopus 로고
    • Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
    • DOI 10.1084/jem.190.3.355
    • van Elsas A, Hurwitz AA, Allison JP. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3): 355-366. (Pubitemid 29374833)
    • (1999) Journal of Experimental Medicine , vol.190 , Issue.3 , pp. 355-366
    • Van Elsas, A.1    Hurwitz, A.A.2    Allison, J.P.3
  • 75
    • 78449243489 scopus 로고    scopus 로고
    • Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade
    • Weber J. 2010. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 37(5):430-439.
    • (2010) Semin Oncol , vol.37 , Issue.5 , pp. 430-439
    • Weber, J.1
  • 76
    • 78650212294 scopus 로고    scopus 로고
    • GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer
    • Williams P, Galipeau J. 2011. GMCSF-interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. J Intern Med 269(1):74-84.
    • (2011) J Intern Med , vol.269 , Issue.1 , pp. 74-84
    • Williams, P.1    Galipeau, J.2
  • 77
    • 77954242768 scopus 로고    scopus 로고
    • A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo
    • Williams P, Rafei M, Bouchentouf M, Raven J, Yuan S, Cuerquis J, Forner KA, Birman E, Galipeau J. 2010. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 18(7):1293-1301.
    • (2010) Mol Ther , vol.18 , Issue.7 , pp. 1293-1301
    • Williams, P.1    Rafei, M.2    Bouchentouf, M.3    Raven, J.4    Yuan, S.5    Cuerquis, J.6    Forner, K.A.7    Birman, E.8    Galipeau, J.9
  • 79
    • 77949655286 scopus 로고    scopus 로고
    • Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model
    • Zhao F, Dou J, He XF, Wang J, Chu L, Hu W, Yu F, Wu Y, Gu N. 2010. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 28(16):2846-2852.
    • (2010) Vaccine , vol.28 , Issue.16 , pp. 2846-2852
    • Zhao, F.1    Dou, J.2    He, X.F.3    Wang, J.4    Chu, L.5    Hu, W.6    Yu, F.7    Wu, Y.8    Gu, N.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.